Navigation Links
Most men with low-risk prostate cancer receive aggressive treatment
Date:7/26/2010

Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

More than 90 percent of all prostate cancers are diagnosed before the disease has spread to other parts of the body, and the five-year survival rate for these patients diagnosed with localized disease is almost 100 percent, according to background information in the article. The five-year survival rate from all stages of disease increased from 69 percent in 1975 to almost 99 percent in 2003. "The tremendous improvement in survival has been attributed to early detection and treatment," the authors write. "However, there have been concerns about the potential overdiagnosis and overtreatment of localized prostate cancer. Despite these concerns, some researchers argue that the prostate-specific antigen (PSA) level is associated with a continuum of cancer risk and recommend lowering the 4-nanogram per milliliter threshold for biopsy."

To determine current risk profiles and treatment patterns of men with prostate cancer and PSA levels below this threshold, Yu-Hsuan Shao, Ph.D., of the Cancer Institute of New Jersey, New Brunswick, and colleagues used data from the Surveillance, Epidemiology and End Results system. Of 123,934 men with newly diagnosed prostate cancer from 2004 to 2006, 14 percent had PSA levels of 4 nanograms per milliliter or lower. "The patients in these cases were less likely to have high-grade cancer, and more than half were classified as having low-risk cancer," the authors write.

"Despite their lower risk of having clinically significant disease, treatment rates for men with PSA values of 4.0 nanograms per milliliter or lower were comparable to those of men presenting with PSA values between 4.0 and 20.0 nanograms per milliliter." More than 70 percent of men with PSA values lower than 20 nanograms per milliliter had their prostates removed via radical prostatectomy or had radiation therapy. "Radical prostatectomy was performed on 44 percent of men with PSA values of 4.0 nanograms per milliliter or lower, 38 percent of men with PSA values between 4.1 and 10.0 nanograms per milliliter and 24 percent of men with PSA values between 10.1 and 20 nanograms per milliliter. Radiation therapy was performed on 33 percent of men with PSA values of 4.0 nanograms per milliliter or lower, 40 percent of men with PSA values between 4.1 and 10.0 nanograms per milliliter and 41.3 percent of men with PSA values between 10.1 and 20 nanograms per milliliter," the authors write.

The authors suggest that if the threshold PSA value for biopsy were decreased from 4.0 to 2.5 nanograms per milliliter, the number of men with abnormal PSA levels would double to approximately 6 million. "Estimates suggest that 32 percent of men with abnormal PSA levels would be diagnosed as having prostate cancer from their needle biopsy," they write. "Based on the results in the present study, 82.5 percent of these 1.9 million men would receive attempted curative treatments, while only 2.4 percent would have high-grade cancer. However, no evidence suggests that delaying biopsy until the PSA level reaches 4.0 nanograms per milliliter would result in an excessive number of potentially non-curable disease cases."

"These results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions," the authors conclude. "Without the ability to distinguish indolent from aggressive cancers, lowering the biopsy threshold might increase the risk of overdiagnosis and overtreatment."


'/>"/>

Contact: Michele Fisher
fisherm2@umdnj.edu
732-235-9872
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. What is the role of focal therapy in low-risk prostate cancer?
2. Value of Monitoring Low-Risk Prostate Cancer Assessed
3. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
4. Surveillance may be suitable treatment option for patients with low-risk prostate cancer
5. Advance Toward Test for Aggressive Prostate Cancer
6. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
7. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
8. Few differences in outcomes between open and laparoscopic prostate surgery
9. Two Surgical Methods Equally Successful for Prostate Cancer
10. Genetic Mutation Linked to Prostate Cancer in Blacks
11. Statins May Benefit Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... London, May ... honored to serve earlier this month as a Guest Speaker and Contributor to a ... Royal Family and Common Purpose. , Walter Schindler and SAIL ...
(Date:5/23/2017)... Rosa, CA (PRWEB) , ... May 23, 2017 , ... ... mosquito season underway in Sonoma County. While officials call for diligence, asking homeowners to ... are looking at potential health concerns. Along with the annoying buzz of mosquitos is ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... leading equipment provider in the modern ART laboratory, to provide hands-on training utilizing ... Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor , will ...
(Date:5/23/2017)... ... , ... New patients from Charleston, SC, are now welcome to receive a ... SC, with or without a referral. A full mouth reconstruction can transform the appearance ... in Charleston, SC. Those who suffer from gum disease, misaligned teeth or jaw pain ...
(Date:5/23/2017)... ... 2017 , ... New patients with symptoms of gum disease in ... gum disease treatments from the doctors at Art of Dentistry, without first receiving a ... the importance of receiving qualified treatment in order to avoid systemic health effects associated ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/12/2017)... -- The China and Canada joint tech company Laughing ... energy and detergent, and features a powerful disinfection process. ... machine that washes and sanitizes women,s panties or babies, cloth diapers ... ... not require an external water inlet. ...
Breaking Medicine Technology: